Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Poseida Therapeutics Inc. is managing 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 4 distinct examiners and 3 distinct art units, indicating some overlap in the examination units. This distribution shows that the company's biotech applications are being reviewed by a diverse group of examiners, even when they fall within similar technical categories.
LIPPOLIS, ALEXANDRA ROSE is the busiest examiner for the portfolio, handling 1 busiest examiner pending office action. Since each of the 4 pending actions is assigned to a different examiner, the company must manage multiple examiner relationships. This lack of examiner overlap means that the 4 pending office actions are likely to follow independent prosecution paths, even if they share similar technical foundations.
The involvement of 3 distinct art units suggests that the company's innovations are being classified into a few closely related technical areas. This can be beneficial for maintaining some consistency in the types of rejections received, although the 4 distinct examiners will each bring their own interpretation to the cases. Practitioners should focus on the specific requirements of each of the 3 art units while navigating the individual preferences of the examiners involved.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (50%) |
| Double-patenting only | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LIPPOLIS, ALEXANDRA ROSE | 1 | 46.9% | +59.0% |
| CHONG, KIMBERLY | 1 | 72.4% | +13.0% |
| CARTER, SANDRA DILLAHUNT | 1 | 56.2% | +29.0% |
| NOAKES, SUZANNE MARIE | 1 | 73.3% | +18.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18698514 | TRANSPOSON COMPOSITIONS AND METHODS OF USE THEREOF | LIPPOLIS, ALEXANDRA ROSE | — |
| 18696129 | TRANSPOSASE AND USES THEREOF | CHONG, KIMBERLY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18051109 | HYPERACTIVE PIGGYBAC TRANSPOSASES | NOAKES, SUZANNE MARIE | 30d overdue |
| 18351442 | COMPOSITIONS AND METHODS FOR SELECTIVE ELIMINATION AND REPLACEMENT OF HEMATOPOIETIC STEM CELLS | CARTER, SANDRA DILLAHUNT | 14d |
| 18698514 | TRANSPOSON COMPOSITIONS AND METHODS OF USE THEREOF | LIPPOLIS, ALEXANDRA ROSE | — |
| 18696129 | TRANSPOSASE AND USES THEREOF | CHONG, KIMBERLY | — |
| Art Unit | Apps |
|---|---|
| 1657 | 1 |
| 1674 | 1 |
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18698514 | TRANSPOSON COMPOSITIONS AND METHODS OF USE THEREOF | LIPPOLIS, ALEXANDRA ROSE | — | §101§112 | Non-Final OA | — | Pending | Apr 04, 2024 |
| 18696129 | TRANSPOSASE AND USES THEREOF | CHONG, KIMBERLY | 1657 | §101§112 | Non-Final OA | — | Pending | Apr 01, 2024 |
| 18351442 | COMPOSITIONS AND METHODS FOR SELECTIVE ELIMINATION AND REPLACEMENT OF HEMATOPOIETIC STEM CELLS | CARTER, SANDRA DILLAHUNT | 1674 | DP | Final Rejection | 14d | Pending | Jul 12, 2023 |
| 18051109 | HYPERACTIVE PIGGYBAC TRANSPOSASES | NOAKES, SUZANNE MARIE | 1656 | DP | Final Rejection | 30d overdue | Pending | Oct 31, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial